AEON — AEON BIOPHARMA INC

Public company

Sign in to save1 tracked investor reported this
For educational research only.InvestorLens analyzes public regulatory filings (SEC EDGAR, STOCK Act PTRs) that may be delayed by 45 days or more. Information shown is historical and is not financial, legal, or tax advice, nor a recommendation or solicitation to buy or sell any security. Always do your own research.

InvestorLens aggregates public filing data to show which tracked investors reported holdings in this stock. Dollar values represent reported position values, not market capitalization, and may be delayed up to 45 days. Not a recommendation.

Sourced from SEC EDGAR public filings

Why are billionaires buying AEON?

Built from public SEC filings and public economic data. Not a recommendation.

Confidence
95
Institutional Conviction
Net accumulation · 1 buying vs 0 selling last quarter
60
Macro Tailwind
Macro conditions are a headwind for this sector
38
Why? — Evidence & Confidence ▾

Of 1 tracked investors who changed their AEON position last quarter, 1 bought and 0 sold (100% buy-side). Macro conditions are a headwind for this sector (Macro Tailwind 38/100 in a Expansion regime).

Supporting evidence
  • +1 tracked investor added or increased positions last quarter (Ken Griffin)
  • +1 tracked investors reported holding AEON at their latest filing
Contradicting evidence — always shown
  • −Current Expansion regime has historically been a headwind for this sector (Macro Tailwind 38/100)
  • −13F data is disclosed up to 45 days after quarter end — positions may have changed since
Know the limits
  • · 13F disclosure lag (up to 45 days)
  • · Tracked investors are a sample, not the whole market
  • · Sector regime fit is a historical average, not a guarantee

Every InvestorLens score shows its evidence — including what argues against it. Model conviction-v1 · generated 11/22/2026.

About AEON BIOPHARMA INC (AEON)

AEON BIOPHARMA INC (AEON) appears in the most recent 13F filings of 1 tracked institutional investor. The largest disclosed position is held by Izzy Englander (Millennium Management), valued at $649,449. Across recent filings, tracked investors recorded 3 new positions, 0 increased, 0 reduced, and 1 exited. All data sourced from SEC 13F filings.

Smart Money Consensus™

Based on recent institutional activity in AEON

75
/100
Institutional Accumulation
Added / Increased3
Reduced0
Exited1
BearishBullish
Crowded Trade Score™

How many top investors track AEON

7
/100
Undiscovered
1investor

Only 1 tracked investor report this position.

UndiscoveredCrowded
151015+

AEON Ownership Composition

How AEON BIOPHARMA INC is held across tracked investor types, based on reported 13F positions.

Dominant Type
Multi-Strategy / Quant
100% of tracked value
Institutions
1
tracked investors
Total Reported
$16.7K
combined 13F value
Types1
  • Multi-Strategy / Quant100.0%
Multi-Strategy / Quant(1)
100.0%

Tracked investors currently reporting AEON

1 tracked investor has since exited this position — listed separately below.

  • Ken GriffinSep 30, 2026
    Citadel Advisors
    Shares
    55.7K
    Value
    $16.7K
    % Portfolio
    0.00%

Previously held AEON

These investors reported AEON in an earlier quarter but not in their most recent 13F. Figures below are their last reported position, not a current holding.

InvestorFirmLast reported sharesValue thenLast held
Izzy EnglanderMillennium Management51K$53.5KJun 30, 2024

Recent activity

Frequently asked questions

How many institutional investors hold AEON?
1 tracked institutional investor disclosed a position in AEON (AEON BIOPHARMA INC) in their most recent 13F filing.
Who is the largest institutional holder of AEON?
Izzy Englander, Millennium Management, holds the largest disclosed position in AEON, valued at $649,449.
Did institutional ownership of AEON increase or decrease?
Across recent 13F filings, tracked investors recorded 3 new positions, 0 increased, 0 reduced, and 1 fully exited AEON.
Where does this AEON ownership data come from?
SEC Form 13F-HR filings, accessed via EDGAR. 13F filings are disclosed quarterly with a 45-day reporting delay and cover U.S.-listed long equity positions only. This is not investment advice.